Merck and Isofol Sign Agreement for Cancer Drug

11 November 2009 (Last Updated November 11th, 2009 18:30)

Merck Eprova has signed an exclusive license agreement with Isofol Medical for it to use Merck's proprietary folate compound Modufolin in oncology. The use of Modufolin is expected to enhance effectiveness compared to folate compounds now used in cancer treatment, Merck said.

Merck Eprova has signed an exclusive license agreement with Isofol Medical for it to use Merck's proprietary folate compound Modufolin in oncology.

The use of Modufolin is expected to enhance effectiveness compared to folate compounds now used in cancer treatment, Merck said.

The company will provide the drug, which is the active metabolite of Leucovorin, for use in clinical trials as well as commercial drug products.